Optimizing treatment decision by accounting for longitudinal biomarker trajectories and competing risks of each individual
通过考虑每个个体的纵向生物标志物轨迹和竞争风险来优化治疗决策
基本信息
- 批准号:10658050
- 负责人:
- 金额:$ 38.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-12 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:AccountingBenefits and RisksBiological MarkersCessation of lifeChronic DiseaseChronic Kidney FailureChronic Myeloid LeukemiaComputer softwareDataDecision MakingDevelopmentDiabetes MellitusDimensionsDiseaseDisease ProgressionFutureGoalsHealth StatusHeart DiseasesIndividualKidney DiseasesLifeLiteratureMalignant NeoplasmsMean Survival TimesMeasurementMethodsModelingMonitorPatient riskPatientsPatternPerformancePhysiciansPopulationPrincipal Component AnalysisProcessRandomized, Controlled TrialsResearchRiskRisk EstimateSelection for TreatmentsSeriesStatistical MethodsStatistical ModelsStem cell transplantTechniquesTestingTimeVisitWeightaggressive therapydesignflexibilityfollow-upfrailtygraft vs host diseasehigh dimensionalityimprovedleukemiaoptimal treatmentspredictive modelingprognostic modelprogramsrisk predictionsimulationsoftware developmenttemporal measurementtreatment optimizationtreatment strategyuser-friendlyvalidation studiesvectorvirtualvirtual patient
项目摘要
Project Summary/Abstract
The goal of this proposal is to develop statistical methods for evaluating treatment strategies at different
time points and identifying optimal treatment strategies on the basis of patients' longitudinal biomarker
measurements. It is motivated by our research on identifying the best timing for patients with chronic myeloid
leukemia (CML) to receive a stem cell transplant (SCT). SCT can cure leukemia, but it is associated with life-
threatening risks. For this reason, most patients start with other less-aggressive treatment options that are
much safer but cannot cure the disease. Thus the decision-making about optimal timing of SCT depends on a
patient's disease progression. However, it is infeasible to conduct a randomized controlled trial to weigh the
risks and benefits of SCT at various times. To optimize this decision-making process, sophisticated and
comprehensive statistical models are needed to provide an accurate estimation of the benefits and risks (and
their trade-offs) over time for patients under different SCT timing options. However, these have not yet been
developed, due to the challenges elaborated below.
First, the question of an optimal decision on SCT cannot be answered by a single statistical model, it
requires assembling information from a series of models and analyses. Second, there most likely is not a
uniform solution for this question, as the optimal timing of SCT depends on each individual's disease
progression status. Consequently, physicians must use patients' longitudinal biomarker trajectories to monitor
their health status and make treatment decision in a dynamic fashion. Third, the treatment decision for each
individual must account for their competing risks, including death by treatment-related complications and other
causes (e.g., heart diseases and diabetes). Finally, it is impossible to implement optimal decision-making
without an easy-to-use software. The following specific aims are proposed to solve these problems.
Aim 1: Use functional component principal component analysis (FPCA) techniques to fully capture the
dominant patterns from patients' longitudinal biomarker trajectories, and use them as predictors of
patients’ risk of disease progression.
Aim 2: Estimate dynamic competing risks based on baseline covariates and longitudinal biomarker
trajectories using multi-state models.
Aim 3: Use analytic and microsimulation approaches to estimate and compare the mean survival times
under different SCT timing options.
Aim 4: Conduct validation studies, develop software, and broaden application.
Three CML studies will be used to cross-validate each other regarding the optimal timing of SCT. Software
programs with user-friendly interfaces will be made publicly available. The proposed statistical and software
programs will be adapted and applied to a study of kidney disease to test their broad application.
项目总结/摘要
该提案的目标是开发统计方法,用于评估不同年龄段的治疗策略。
时间点,并根据患者的纵向生物标志物确定最佳治疗策略
测量.它的动机是我们的研究确定最佳时机的慢性髓系白血病患者
白血病(CML)接受干细胞移植(SCT)SCT可以治愈白血病,但它与生命有关-
威胁风险。出于这个原因,大多数患者开始与其他侵略性较小的治疗选择,
安全得多,但不能治愈疾病。因此,关于SCT最佳时机的决策取决于
患者的疾病进展。然而,进行随机对照试验来权衡
SCT在不同时期的风险和益处。为了优化这一决策过程,
需要全面的统计模型来提供对获益和风险的准确估计(以及
他们的权衡)随着时间的推移为患者在不同的SCT定时选项。然而,这些尚未被
由于下文所述的挑战,
首先,SCT的最佳决策问题不能通过单一的统计模型来回答,
需要从一系列模型和分析中收集信息。其次,很可能没有一个
对于这个问题的统一解决方案,因为SCT的最佳时机取决于每个人的疾病
进展状态。因此,医生必须使用患者的纵向生物标志物轨迹来监测
他们的健康状况,并以动态的方式做出治疗决定。第三,每个人的治疗决定
个人必须说明他们的竞争风险,包括治疗相关并发症和其他
原因(例如,心脏病和糖尿病)。最后,无法实现最优决策
没有一个简单易用的软件。为解决这些问题,提出了以下具体目标。
目的1:使用功能成分主成分分析(FPCA)技术,以充分捕捉
从患者的纵向生物标志物轨迹的主导模式,并使用它们作为预测
患者疾病进展的风险。
目的2:基于基线协变量和纵向生物标志物估计动态竞争风险
使用多状态模型的轨迹。
目的3:使用分析和微观模拟方法来估计和比较平均生存时间
在不同的SCT定时选项下。
目标4:进行验证研究,开发软件,并扩大应用。
三项CML研究将用于交叉验证SCT的最佳时间。软件
将向公众提供界面友好的程序。拟议的统计和软件
程序将被改编并应用于肾脏疾病的研究,以测试其广泛的应用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xuelin Huang其他文献
Xuelin Huang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xuelin Huang', 18)}}的其他基金
Core 3: Biostatistics, Data Management, and Bioinformatics
核心 3:生物统计学、数据管理和生物信息学
- 批准号:
10931066 - 财政年份:2023
- 资助金额:
$ 38.49万 - 项目类别:
Core 3: Biostatistics, Data Management, and Bioinformatics
核心 3:生物统计学、数据管理和生物信息学
- 批准号:
10006810 - 财政年份:2003
- 资助金额:
$ 38.49万 - 项目类别:
Core 3: Biostatistics, Data Management, and Bioinformatics
核心 3:生物统计学、数据管理和生物信息学
- 批准号:
10247501 - 财政年份:2003
- 资助金额:
$ 38.49万 - 项目类别:
Data and Omics Sciences Core (DATAOmics)
数据和组学科学核心 (DATAOmics)
- 批准号:
10020957 - 财政年份:2002
- 资助金额:
$ 38.49万 - 项目类别:
Data and Omics Sciences Core (DATAOmics)
数据和组学科学核心 (DATAOmics)
- 批准号:
10249307 - 财政年份:2002
- 资助金额:
$ 38.49万 - 项目类别:
Data and Omics Sciences Core (DATAOmics)
数据和组学科学核心 (DATAOmics)
- 批准号:
10466876 - 财政年份:2002
- 资助金额:
$ 38.49万 - 项目类别:
Core 3: Biostatistics, Data Management, and Bioinformatics
核心 3:生物统计学、数据管理和生物信息学
- 批准号:
9762855 - 财政年份:
- 资助金额:
$ 38.49万 - 项目类别:
相似海外基金
EPIC-Oxford: benefits and risks of plant-based diets
EPIC-Oxford:植物性饮食的好处和风险
- 批准号:
MR/Y013662/1 - 财政年份:2024
- 资助金额:
$ 38.49万 - 项目类别:
Research Grant
HYDRA: Hydrogen Economy Benefits and Risks: Tools Development and Policies Implementation to Mitigate Possible Climate Impacts
HYDRA:氢经济的好处和风险:减轻可能的气候影响的工具开发和政策实施
- 批准号:
10089618 - 财政年份:2023
- 资助金额:
$ 38.49万 - 项目类别:
EU-Funded
Coldfish: potential benefits and risks of borealisation for fish stocks and ecosystems in a changing Arctic Ocean
冷鱼:北冰洋变化中鱼类种群和生态系统的北化的潜在好处和风险
- 批准号:
NE/R012520/1 - 财政年份:2018
- 资助金额:
$ 38.49万 - 项目类别:
Research Grant
Coldfish: potential benefits and risks of borealisation for fish stocks and ecosystems in a changing Arctic Ocean
冷鱼:北冰洋变化中鱼类种群和生态系统的北化的潜在好处和风险
- 批准号:
NE/R012563/1 - 财政年份:2018
- 资助金额:
$ 38.49万 - 项目类别:
Research Grant
The use of big data for social policy: benefits and risks
大数据在社会政策中的应用:好处和风险
- 批准号:
LA170100011 - 财政年份:2017
- 资助金额:
$ 38.49万 - 项目类别:
Learned Academies Special Projects
Long-term Benefits and Risks of Bariatric Surgery in Integrated Care Systems
综合护理系统中减肥手术的长期益处和风险
- 批准号:
9329410 - 财政年份:2015
- 资助金额:
$ 38.49万 - 项目类别:
Long-term Benefits and Risks of Bariatric Surgery in Integrated Care Systems
综合护理系统中减肥手术的长期益处和风险
- 批准号:
9136837 - 财政年份:2015
- 资助金额:
$ 38.49万 - 项目类别:
Long-term Benefits and Risks of Bariatric Surgery in Integrated Care Systems
综合护理系统中减肥手术的长期益处和风险
- 批准号:
8940898 - 财政年份:2015
- 资助金额:
$ 38.49万 - 项目类别:
Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceuticals: An IOM Workshop
描述和传达药品效益和风险评估中的不确定性:IOM 研讨会
- 批准号:
8996009 - 财政年份:2015
- 资助金额:
$ 38.49万 - 项目类别:
ADOLESCENT BARIATRICS ASSESSING HEALTH BENEFITS AND RISKS
青少年肥胖症患者评估健康益处和风险
- 批准号:
8356702 - 财政年份:2010
- 资助金额:
$ 38.49万 - 项目类别: